<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dengue virus infection: Prevention and treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dengue virus infection: Prevention and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dengue virus infection: Prevention and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen J Thomas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan L Rothman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anon Srikiatkhachorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siripen Kalayanarooj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dengue is a febrile illness caused by a flavivirus transmitted by <em>Aedes aegypti or Aedes albopictus</em> mosquitoes while taking a blood meal. There are four dengue virus (DENV) types (DENV-1, DENV-2, DENV-3, and DENV-4), all of which are capable of inducing severe disease (dengue hemorrhagic fever [DHF]/dengue shock syndrome [DSS]). Dengue is endemic in more than 125 countries in tropical and subtropical regions and causes an estimated 390 million infections annually worldwide, of which 96 million are clinically apparent [<a href="#rid1">1</a>].</p><p>The likelihood for development of severe dengue is highest among individuals who are infected a second time by a different DENV type from the first infection (known as secondary or heterotypic infection) [<a href="#rid2">2</a>]. Thus, severe disease occurs primarily among individuals in areas where multiple DENV types circulate simultaneously. Infection with DENV provides long-term protection against disease caused by reinfection with that particular type. However, infection provides only short-lived cross-protection to the other three DENV types.</p><p>There are numerous documents providing guidance on the optimal approaches to managing dengue [<a href="#rid3">3-6</a>]. Data from well-designed randomized controlled trials are limited. The guidance in this document largely agrees with published guidelines and is also based on the contributors' clinical experience in management of complex DENV infections.</p><p>Measures to prevent DENV infection and supportive treatment following infection and the development of disease will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3028.html" rel="external">"Dengue virus infection: Epidemiology"</a> and  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>DENV transmission occurs when susceptible hosts, DENVs, and mosquitoes capable of transmission are co-located in space and time. Infection risk exists for anyone living in or traveling in a dengue-endemic region, especially in tropical Asia, Central and South America, and the Caribbean. In most of these regions, DENV transmission occurs year-round. However, the greatest risk of infection tends to be seasonal or during a recognized outbreak.</p><p class="headingAnchor" id="H3"><span class="h2">In endemic areas</span><span class="headingEndMark"> — </span>Approaches for the prevention of DENV infection and disease in endemic areas include mosquito control, personal protective measures, and vaccination.</p><p class="headingAnchor" id="H1948185557"><span class="h3">Personal protection from infection</span></p><p class="headingAnchor" id="H2275284310"><span class="h4">Mosquito repellants</span><span class="headingEndMark"> — </span>Issues related to personal protection for prevention of mosquito bites are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p class="headingAnchor" id="H2495671637"><span class="h4">Insecticide spraying</span><span class="headingEndMark"> — </span>Distribution of insecticide-treated curtains was successful in reducing populations of <em>A. aegypti</em> mosquitoes for up to 18 months in several studies [<a href="#rid7">7,8</a>] and was associated with reduced human and mosquito infections with DENV in one region [<a href="#rid7">7,8</a>], although use of the curtains declined with time. Insecticide spraying in response to dengue outbreaks is not highly effective, since <em>A. aegypti</em> mosquitoes frequently breed inside houses [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H1575701918"><span class="h4">Vaccine development</span><span class="headingEndMark"> — </span>Infection with one DENV type provides long-term protection against reinfection with that same type, supporting the feasibility of an effective dengue vaccine. Following infection with one type, there is short-lived immunity and cross-protection against disease caused by the other three DENV types [<a href="#rid11">11</a>].</p><p>In view of the association between previous exposure to DENV types and severe disease, and the recognition that all four DENV types are capable of causing severe disease, ideally any candidate vaccine should produce protective immunity against all four DENV types (tetravalent immunity). Since waning immunity might also increase the risk for severe disease in vaccine recipients, vaccine-induced protective immunity should be long lived [<a href="#rid12">12</a>]. Given that the rate of clinically relevant third or fourth DENV infection is low, it is unclear whether tetravalent immunity is required for efficacy [<a href="#rid13">13</a>].</p><p>One vaccine, CYD-TDV (Dengvaxia), has been licensed in over 20 countries in Latin America and Southeast Asia (first licensed in 2015) (see <a class="local">'CYD-TDV (Dengvaxia)'</a> below). Vaccines in advanced clinical development include TAK-003 (Takeda) (see <a class="local">'TAK-003'</a> below) and a tetravalent, live-virus vaccine attenuated through directed mutagenesis with a DENV-2/-4 chimeric strain (National Institute of Health, licensed to Bhutantan and Merck) [<a href="#rid14">14-16</a>].</p><p class="headingAnchor" id="H1605460081"><span class="h5">CYD-TDV (Dengvaxia)</span><span class="headingEndMark"> — </span>In 2018, the CYD-TDV (Dengaxia) vaccine was approved by European authorities and recommended by the World Health Organization (WHO) for persons aged 9 to 45 years with confirmed previous dengue infection who live in endemic areas [<a href="#rid17">17-19</a>]. In 2019, the United States Food and Drug Administration (FDA) approved the vaccine for use in endemic areas [<a href="#rid20">20</a>]. In 2021, the Advisory Committee on Immunization Practices (ACIP) of the United States Centers for Disease Control and Prevention (CDC) officially recommended the vaccine for children aged 9 to 16 who have serologic evidence of previous dengue infection and live in endemic US territories [<a href="#rid21">21</a>]. Among United States territories, dengue is endemic in Puerto Rico, American Samoa, and the US Virgin Islands. The vaccine is not approved for travelers visiting dengue-endemic areas and is not commercially available in the United States [<a href="#rid17">17</a>]. </p><p>CYD-TDV is a formulation of four chimeric yellow fever 17D-dengue vaccine viruses, where the premembrane and envelope proteins from each of the four DENV types replaces the same proteins in a yellow fever 17D backbone virus [<a href="#rid22">22,23</a>]. The basis for licensure was two large phase III randomized controlled trials of CYD-TDV; results were reported in 2014 to 2015 [<a href="#rid24">24,25</a>]. One trial was conducted in five countries in the Asia-Pacific region and enrolled children aged 2 to 14 years [<a href="#rid24">24</a>]; the other trial was conducted in five countries in Latin America and the Caribbean and enrolled children aged 9 to 16 years [<a href="#rid25">25</a>]. The age groups were chosen based on likely target populations for vaccination and epidemiologic data of clinical attack rates.</p><p>In both trials, the CYD-TDV vaccine was administered in three doses at months 0, 6, and 12. Results from the two trials were comparable; in the primary per-protocol analysis, vaccine efficacy was 57 and 61 percent against virologically confirmed dengue of any severity caused by any DENV type that occurred between 28 days and 13 months after the third vaccine dose. Vaccine efficacy was higher against dengue hemorrhagic fever or dengue infection requiring hospitalization (80 to 95 percent). Vaccine efficacy varied by serotype and was significantly higher for DENV-3 and DENV-4 (approximately 75 percent) than DENV-1 (50 percent) and DENV-2 (35 to 42 percent). Vaccine efficacy was lower (34 to 36 percent) in children 2 to 5 years of age and in children who did not have detectable dengue-neutralizing antibodies prior to vaccination. The safety profile was considered good, and there was no indication of more severe dengue disease in breakthrough cases in vaccine recipients that occurred over the 25 months of active case surveillance.</p><p>Follow-up analyses of these vaccine trials found significant limitations of the vaccine [<a href="#rid26">26-28</a>]. In a case-cohort study in which data from three vaccine efficacy trials were reanalyzed, the vaccine was protective among children previously exposed to dengue but increased the risk of hospitalization and severe illness among children who were not previously exposed [<a href="#rid26">26</a>]. Among dengue-seronegative children age 2 to 16 years, the cumulative incidence of hospitalization for dengue among vaccine recipients and controls was 3.06 and 1.87 percent, respectively (hazard ratio [HR] 1.75, 95% CI 1.14-2.70). Among dengue-seropositive children age 2 to 16 years, the cumulative incidence of hospitalization for dengue among vaccine recipients and controls was 0.75 and 2.47 percent, respectively (HR 0.32, 95% CI 0.23-0.45).</p><p>In November 2017, the vaccine manufacturer announced that, based on six years of clinical data, the vaccine had a persistent beneficial effect in individuals who had been previously infected with DENV prior to vaccination. In individuals with no prior episode of DENV infection, however, vaccination was associated with an increased risk of severe disease and hospitalization. Therefore, the manufacturer updated the label, advising that individuals with no prior DENV infection forgo vaccination [<a href="#rid29">29</a>].</p><p>In December 2017, the WHO issued a statement indicating that the vaccine is protective against severe dengue for individuals with dengue seropositivity at the time of first vaccination but that the risk of severe dengue is significantly increased for individuals with dengue seronegativity at the time of first vaccination [<a href="#rid30">30</a>].</p><p>The mechanisms for CYD-TDV vaccine efficacy in seropositive individuals and the increased risk of severe dengue in seronegative individuals are uncertain. Only a subset of individuals underwent scheduled serologic monitoring prior to and following vaccination, so analyses of the immune profiles associated with various outcomes are limited. A statistical analysis found that higher postvaccination titers of neutralizing antibodies were associated with a significantly higher vaccine efficacy for all DENV types, baseline serostatus groups, and age groups [<a href="#rid31">31</a>]. However, no absolute correlate of protection could be identified, indicating that the relationship between vaccine-induced immune responses and efficacy is likely more complex than any one single factor.</p><p>The vaccine sponsor also used measured (when values were available) or imputed (when values missing) PRNT50 titers, with imputation conducted using covariates to include data generated from study month 13 blood samples (on month after dose 3) tested with a newly developed anti-non-structural protein 1 (NS1) assay. Because the vaccine construct does not contain dengue NS1 protein, the absence of anti-NS1 antibodies from a study month 13 sample would indicate the individual had not experienced a natural DENV infection (seronegative status at baseline) [<a href="#rid26">26,32</a>].</p><p>Overall, CYD demonstrated superior efficacy and clinical benefit in seropositive versus seronegative vaccine recipients. There was also a trend of superior efficacy and beneficial vaccine effect in older children, and these effects were noted against any dengue caused by all DENV types as well as severe and hospitalized dengue. In contrast, there was a clear safety signal in seronegative vaccine recipients especially in the younger age groups with hospitalization and severe disease occurring with increased frequency in seronegative vaccine recipients [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H448826989"><span class="h5">TAK-003</span><span class="headingEndMark"> — </span>TAK-003 is tetravalent vaccine based on an attenuated laboratory-derived DENV-2 virus, DENV-2 primary dog kidney (PDK)–53, which provides the genetic backbone for all four of the viruses in the vaccine [<a href="#rid34">34-37</a>]. The other three virus strains (TDV-1, TDV-3, and TDV-4) are chimeras generated by replacing the premembrane and envelope genes of TDV-2 with those from wild-type DENV-1, DENV-3, and DENV-4 strains.</p><p>Findings from a phase 2 trial among more than 1400 participants aged 2 to 17 years in three countries with 48-month follow-up support a two-dose schedule administered three months apart [<a href="#rid35">35</a>]. No serious adverse events or severe DENV disease were reported. </p><p>In a phase 3 clinical trial including more than 20,000 children 4 to 16 years of age in regions of Asia and Latin America where DENV infection is endemic, individuals were randomly assigned to receive two doses of vaccine or placebo three months apart [<a href="#rid36">36,37</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>At 12 months of follow-up, fewer cases of DENV infection (confirmed via polymerase chain reaction) were observed among vaccinated individuals than among those who received placebo (0.5 versus 2.5 per 100-person years); the overall vaccine efficacy was 80.9 percent (95% CI 75.2-85.3) [<a href="#rid36">36</a>]. Approximately 5200 individuals (28 percent of the per-protocol population) were seronegative at baseline; in this group, the vaccine efficacy was 74.9 percent (95% CI 57.0-85.4). The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1 and 3.8 percent, respectively). Efficacy varied according to DENV type; there was no efficacy against DENV-3, and data were insufficient to evaluate efficacy against DENV-4. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At 18 months of follow-up, overall vaccine efficacy (against any DENV type and any disease severity) was 73.3 percent (95% CI 66.5-78.8) and overall efficacy against hospitalized dengue was 90.4 percent (95% CI 82.6-94.7) [<a href="#rid37">37</a>]. Vaccine efficacy was higher among baseline seropositive than seronegative individuals (76.1 versus 66.2 percent). Secondary vaccine efficacy endpoints by serotype were met for DENV-1 (69.8 percent, 95% CI 54.8-79.9), DENV-2 (95.1 percent, 95% CI 89.9-97.6), and DENV-3 (48.9 percent, 95% CI 27.2-64.1), but not DENV-4 (51.0 percent, 95% CI -69.4 to 85.8). Vaccine efficacy against DENV-1 and DENV-2 was similar regardless of baseline serostatus; for DENV-3, vaccine efficacy among seropositive individuals was 61.8 percent (43.0 to 74.4) but vaccine efficacy was not observed among seronegative individuals (-68.2 percent, 95% CI -318.9 to 32.4). </p><p></p><p>Thus far, the available data suggest TAK-003 may be used in seropositive or seronegative individuals, and the high efficacy against hospitalized dengue suggests that TAK-003 may be a useful public health tool for reducing the burden of severe disease. However, further efficacy and safety evaluation is needed, particularly for serotypes DENV-3 and DENV-4.</p><p class="headingAnchor" id="H20677290"><span class="h3">Mosquito control</span><span class="headingEndMark"> — </span>Mosquito control is effective but is difficult to resource and sustain. Programs in the 1940s through 1970s targeting the <em>A. aegypti</em> mosquito via aggressive surveillance and insecticide use for elimination of urban yellow fever in the Americas were successful at reducing transmission of yellow fever as well as the DENVs [<a href="#rid9">9</a>]. Lack of funding and attention for these programs led to reemergence of <em>A. aegypti</em> and corresponding re-emergence of dengue.</p><p>Some approaches to mosquito control for prevention of DENV infection are described below. Additional issues related to mosquito vector control are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5702.html" rel="external">"Malaria: Epidemiology, prevention, and control", section on 'Mosquito control'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing breeding sites – Community-based education to reduce breeding sites that accumulate standing water (such as discarded tires and other containers) have shown some promise [<a href="#rid9">9,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Larva control – Seeding water vessels with copepods that feed on mosquito larvae was successful in eliminating <em>A. aegypti </em>and dengue transmission in one study including 32 rural communities in Vietnam [<a href="#rid39">39</a>], although this strategy is difficult to apply in urban areas [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endosymbiotic control – A novel dengue control strategy consists of releasing mosquitoes infected with <em>Wolbachia, </em>an obligate intracellular bacterium [<a href="#rid41">41-43</a>]. <em>A. aegypti </em>mosquitoes infected with <em>Wolbachia </em>are less susceptible to DENV infection than wild-type <em>A. aegypti </em>[<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">This strategy was applied in a cluster-randomized controlled trial in Indonesia in which 24 geographic clusters were randomly assigned to receive deployments o<em>f Wolbachia</em>-infected<em> A. aegypti </em>mosquitoes (intervention) or no deployments (control) [<a href="#rid45">45</a>]. Among more than 8000 participants age 3 to 45 years presenting with acute undifferentiated fever during the two-year study period, the incidence of symptomatic dengue was lower in the intervention cluster (2.3 versus 9.4 percent; odds ratio 0.23, 95% CI 0.15-0.35). The efficacy of the intervention for protection against dengue infection was 77.1 percent (95% CI 65.3-84.9) and was similar for all four DENV serotypes; the efficacy for protection against hospitalization was 86.2 percent (95% CI 66.2-94.3). Further study is needed to evaluate the durability of<em> </em>protection afforded by<em> Wolbachia</em>-infected mosquitoes and to reproduce these findings in other contexts.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Among travelers</span><span class="headingEndMark"> — </span>The primary approach to prevention of DENV infections in travelers consists of avoiding exposure to infected <em>A. aegypti</em> mosquitoes, which predominantly live in urban areas (in and around houses) and are most active during the daytime as well as at twilight [<a href="#rid10">10</a>]. Remaining in well-screened or air-conditioned buildings during the day can reduce the risk of exposure. When outside during the day, individuals should wear clothing that reduces the amount of exposed skin and should use an effective mosquito repellent, such as N,N-diethyl-metatoluamide (DEET). (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p>Most travelers from nonendemic countries are at exceedingly low risk for severe dengue in the absence of prior DENV exposure; potential exceptions include frequent international travelers, expatriates, frequently deploying military personnel, and immigrants from endemic areas returning to their countries of origin.</p><p>People with history of dengue infection need not avoid subsequent travel to dengue-endemic regions. Severe dengue occurs in a small number of secondary infections (2 to 4 percent), so the risk of severe dengue in travelers is very low.</p><p>CYD-TDV (Dengvaxia) is not approved for travelers visiting dengue-endemic areas and is not commercially available in the United States [<a href="#rid17">17</a>]. (See <a class="local">'CYD-TDV (Dengvaxia)'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT APPROACH</span><span class="headingEndMark"> — </span>There is no direct antiviral therapy available against the DENVs. Management is supportive, which largely consists of maintaining adequate intravascular volume.</p><p>Treatment guidelines have been published by the World Health Organization (WHO; 2009) and the WHO South-East Asia Regional Office (SEARO; 2011); there are variations between these guidelines [<a href="#rid5">5,46</a>]. These are discussed in the following sections, which follow the framework of the revised dengue case classification. Where relevant, significant differences in the recommendations are noted in the discussion below. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p>Thus far, there has been no prospective validation of the approaches summarized in the WHO guidelines. The areas of greatest uncertainty are the sensitivity and specificity of the criteria used for hospitalization and for initiation of fluid therapy. Some additional clinical approaches that have been successful in endemic areas are discussed below. (See <a class="local">'Additional approaches to management'</a> below.)</p><p>A definitive laboratory diagnosis of dengue is often not available at the point of care; therefore, it is also important to consider other treatable diagnoses. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H13084971"><span class="h2">Phases of infection and clinical assessment</span><span class="headingEndMark"> — </span>DENV infection has three phases: a febrile phase, a critical (plasma leakage) phase, and a convalescent (reabsorption) phase [<a href="#rid5">5</a>]. The febrile phase is characterized by a sudden high-grade fever and dehydration typically lasting two to seven days. The critical phase is characterized by plasma leakage, bleeding, shock, and organ impairment; it usually starts around the time of defervescence (typically days 3 to 7 of infection) and lasts for 24 to 48 hours. The convalescent phase may be characterized by fatigue that can last for days to weeks. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis", section on 'Phases of infection'</a>.)</p><p>The WHO classification schemes for DENV infection are summarized separately [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis", section on 'Classification schemes'</a>.)</p><p>Patients with suspected dengue should be assessed carefully and directed to the appropriate care setting. Early recognition of progression to severe disease and patients at increased risk for severe disease is essential, with prompt initiation of more aggressive therapy when necessary.</p><p>Outpatient management is appropriate for patients with presumptive diagnosis of dengue infection in the absence of warning signs or coexisting conditions (pregnancy, infancy, old age, diabetes, renal failure, underlying hemolytic disease, obesity, or poor social situation); such patients should be able to tolerate oral fluids, urinate at least once every six hours, and have near normal blood counts [<a href="#rid5">5</a>].</p><p>Inpatient management is warranted for patients with dengue and warning signs of severe infection, severe dengue infection, or dengue infection with coexisting conditions  (<a class="graphic graphic_algorithm graphicRef109849" href="/z/d/graphic/109849.html" rel="external">algorithm 1</a>). Dramatic plasma leakage can develop suddenly; early identification of patients at increased risk for shock and other complications is critical. The period of maximum risk for shock is between the third and seventh day of illness, which typically coincides with resolution of fever. In general, plasma leakage first becomes evident between 24 hours before and 24 hours after defervescence.</p><p>Laboratory abnormalities include derangements in blood counts and liver function tests. An elevated hematocrit is an indication that plasma leakage has already occurred and that fluid repletion is required. Confounding factors should be considered when interpreting the hematocrit, including dehydration (associated with increased hematocrit) and hemorrhage (associated with reduced hematocrit). Marked thrombocytopenia (≤100,000/mm<sup>3</sup>) is a criteria for dengue hemorrhagic fever and usually precedes overt plasma leakage. Mild elevations in serum transaminases are common in the setting of dengue infection; transaminase levels are significantly elevated in patients with DHF. In addition, elevated aspartate transaminase (AST) levels are common relatively early in the course of illness; in one Thai study, a normal AST level was a strong negative predictor of DHF (negative predictive value 0.96) [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis", section on 'Dengue hemorrhagic fever'</a>.)</p><p class="headingAnchor" id="H3395051"><span class="h3">Outpatient management</span><span class="headingEndMark"> — </span>Outpatient management is appropriate for patients with presumptive diagnosis of dengue in the absence of warning signs or coexisting conditions as summarized in the preceding section. Most patients with dengue do not develop severe illness and can be safely managed in the outpatient setting. (See <a class="local">'Phases of infection and clinical assessment'</a> above.)</p><p>Patients should be instructed regarding the warning signs of severe dengue infection and the critical phase that follows defervescence (which lasts for 24 to 48 hours); during this period, patients may deteriorate rapidly. During the febrile phase (lasting two to seven days) and the subsequent critical phase (lasting one to two days), the patient should be evaluated daily from the third day of illness through the end of the critical phase for signs of dehydration and other warning signs of severe dengue. Serial blood counts should be followed to evaluate for interval increases in hematocrit concurrent with rapid decrease in platelet count, indicating presence of plasma leakage and increased risk of bleeding complications.</p><p>Fever may be controlled with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>; nonsteroidal anti-inflammatory drugs and aspirin-based products should not be used out of concern for their effect on platelet function and the potential increased risk for bleeding. (See <a class="local">'Management of fever'</a> below.)</p><p>Patients should be instructed to take plenty of fluids and watch for signs of dehydration (decrease in urination, few or no tears, dry mouth or lips, sunken eyes, listlessness or confusion, cold or clammy extremities, sunken fontanel in an infant); these findings warrant prompt clinical evaluation. As fever declines (three to eight days after onset of symptoms), patients should be instructed to seek prompt attention for any of the following: severe abdominal pain, persistent vomiting, skin rash, bleeding from nose or gums, vomiting blood, dark stools, drowsiness or irritability, pale or cool skin, and difficulty breathing.</p><p>Patients in endemic areas should take measures to prevent DENV transmission. If possible, all mosquitoes in the house should be eliminated, screens should be placed on windows and doors to prevent mosquitoes from coming into the house, and containers holding standing water should be emptied. To avoid infecting mosquitoes (which can in turn infect others in the household), if possible, the patient should sleep under a bed net and use insect repellant while ill.</p><p class="headingAnchor" id="H3395080"><span class="h3">Inpatient management</span><span class="headingEndMark"> — </span>Inpatient management is warranted for patients with dengue and warning signs of severe infection, severe dengue infection, or dengue infection with coexisting conditions (pregnancy, infancy, diabetes, poor social situation, old age, or renal failure). (See <a class="local">'Phases of infection and clinical assessment'</a> above.)</p><p>Patients warranting inpatient management should be assessed for signs of impending shock  (<a class="graphic graphic_table graphicRef109848" href="/z/d/graphic/109848.html" rel="external">table 1</a>). In the absence of shock, patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109849" href="/z/d/graphic/109849.html" rel="external">algorithm 1</a>) [<a href="#rid3">3</a>]. Most patients who present for medical attention before profound shock develops and who receive appropriate fluid therapy recover quickly.</p><p>In setting of shock (normal systolic pressure but rising diastolic pressure with narrowing pulse pressure), patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109851" href="/z/d/graphic/109851.html" rel="external">algorithm 2</a>). In the setting of profound or prolonged shock (hypotension, narrow pulse pressure [systolic minus diastolic pressure ≤20 mmHg]), patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109850" href="/z/d/graphic/109850.html" rel="external">algorithm 3</a>).</p><p class="headingAnchor" id="H8"><span class="h2">Management of fever</span><span class="headingEndMark"> — </span>Fever and myalgias should be managed with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (maximum 60 mg/kg/day in children; 4 g/day in adults). <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> or nonsteroidal anti-inflammatory agents should be avoided because of the risk of bleeding complications and because of the potential risk of Reye's syndrome in children. (See  <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">"Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Management of plasma leakage</span><span class="headingEndMark"> — </span>Plasma leakage should be managed with intravascular volume repletion to prevent or reverse hypovolemic shock  (<a class="graphic graphic_algorithm graphicRef109849" href="/z/d/graphic/109849.html" rel="external">algorithm 1</a>). In mild cases, particularly when medical attention is received early, oral rehydration may be sufficient. Administration of intravenous fluid is warranted in patients with established intravascular volume loss. Blood transfusion is appropriate in patients with significant bleeding or low hematocrit and failure to improve with fluid resuscitation. Subsequent hematocrit measurements must be interpreted with caution since it is critical to assess the adequacy of both blood and fluid repletion; in complex cases, it can be challenging to distinguish whether a decrease in hematocrit reflects volume repletion or blood loss.</p><p class="headingAnchor" id="H11"><span class="h3">Treatment of shock</span><span class="headingEndMark"> — </span>Protocols for intravenous fluid therapy have been developed by the World Health Organization [<a href="#rid4">4,5,46</a>] ; these are summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef109851" href="/z/d/graphic/109851.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef109850" href="/z/d/graphic/109850.html" rel="external">algorithm 3</a>). There are a number of acceptable approaches to management of shock associated with dengue, and there are no clinical trial data favoring one approach over the other. The process of frequent clinical assessment is critical to ensure judicious fluid resuscitation and detection of hemorrhage if present.</p><p>Initial fluid resuscitation with crystalloid is appropriate; there is no clinical advantage of colloid over crystalloid [<a href="#rid48">48-50</a>]. In one randomized trial including 512 Vietnamese children with moderate dengue shock syndrome, outcomes were similar with Ringer's lactate, 6% dextran 70, and 6% hydroxyethyl starch [<a href="#rid50">50</a>], establishing that Ringer's lactate is a safe, effective, and inexpensive crystalloid solution for initial resuscitation of patients with moderate shock. In patients with severe shock, dextran and starch performed similarly, although dextran was associated with more hypersensitivity reactions.</p><p>Intravenous colloid solution is warranted for patients with intractable shock resistant to crystalloid resuscitation; in such cases, we favor 10% dextran 40 in normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. Patients with persistent hypoperfusion and falling hematocrit require blood transfusion and should be evaluated for occult or overt bleeding. Other possible complications (such as acidosis, hypoglycemia, and hypocalcemia) should be investigated and corrected as needed. (See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6389.html" rel="external">"Hypovolemic shock in children in resource-abundant settings: Initial evaluation and management"</a>.)</p><p>Once hemodynamic stability has been restored, intravenous fluids should be continued with gradual reduction of the infusion rate over the next 24 to 48 hours. There have been no controlled comparisons of infusion regimens; we typically reduce the infusion rate as follows: 10 mL/kg over the first hour, then 7 mL/kg/hour for 1 to 2 hours, 5 mL/kg/hour for 4 to 6 hours, and 3 mL/kg/hour for 6 to 12 hours. This gradual reduction is intended to minimize the risk of recurrent shock and volume overload. The patient's clinical status (including vital signs, urine output, and hematocrit) should be evaluated prior to each infusion rate adjustment.</p><p>Close clinical observation is essential even after restoration of normovolemia; the 24 hours following initial resuscitation is a period of increased vascular permeability, and patients can develop recurrent shock during this period. Fluid lost into potential spaces (pleura, peritoneum) during the period of plasma leakage is reabsorbed rapidly. Therefore, intravenous fluid supplementation should be discontinued following the period of increased vascular permeability; excessive fluid administration after this point can precipitate hypervolemia and pulmonary edema.</p><p>Monitoring of volume status by other means, such as serial ultrasonographic measurements of the inferior vena cava, may be useful, but conclusive evidence for the use of these techniques in the clinical monitoring of dengue is still lacking [<a href="#rid51">51,52</a>].</p><p>In the absence of complications from prolonged hypotension, most patients with severe dengue infection recover within a few days [<a href="#rid53">53</a>]. Discharge from the hospital is appropriate when patients have been afebrile for at least 24 hours or have passed two days after an episode of shock, are clinically well, and have normal appetite, urine output, and hematocrit.</p><p class="headingAnchor" id="H88969804"><span class="h2">Management of bleeding</span><span class="headingEndMark"> — </span>Gastrointestinal bleeding, epistaxis, or heavy menstrual bleeding may be severe enough to warrant blood transfusion. Significant internal bleeding should be suspected in patients with signs of intravascular hypovolemia without elevation of hematocrit. In these circumstances, blood transfusion should be performed (5 mL/kg of packed red blood cells or 10 mL/kg whole blood in children; 1 unit of packed red blood cells or whole blood in adults). The clinical response and posttransfusion hematocrit should be monitored. (See  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>.)</p><p>Factors that contribute to bleeding include thrombocytopenia due to decreased platelet survival [<a href="#rid54">54</a>] and, in severe cases, prolonged prothrombin time (international normalized ratio &gt;1.3) and frank disseminated intravascular coagulation due to liver failure. Platelet transfusion has not been shown to be effective at preventing or controlling hemorrhage but may be warranted in patients with severe thrombocytopenia (&lt;10,000/mm<sup>3</sup>) and active bleeding. In general, the preponderance of data does not support a role for prophylactic platelet transfusion in patients with severe thrombocytopenia in the absence of active bleeding [<a href="#rid5">5,55-60</a>]. Administration of intravenous <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> is warranted for patients with severe liver dysfunction or prolonged prothrombin time [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H13085392"><span class="h1">ADDITIONAL APPROACHES TO MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment guidelines have been published by the World Health Organization (WHO; 2009) and the WHO South-East Asia Regional Office (SEARO; 2011); there are variations between these guidelines [<a href="#rid4">4,5,47</a>].</p><p>Clinical practice is informed by the above guidelines as well as clinical experiences with managing dengue in different populations. There have been no rigorous trials comparing clinical approaches or establishing endpoints (clinical or laboratory based) for management of severe disease.</p><p>The following indications for inpatient admission have been used at the Queen Sirikit National Institute for Child Health in Bangkok, Thailand, since 1999 [<a href="#rid61">61,62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Shock or impending shock</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukopenia (white blood cell count 5000 cells/mm<sup>3</sup> or lower) and/or thrombocytopenia (platelet count 100,000 cells/mm<sup>3</sup> or lower), especially in high-risk patients (infants, older adults, pregnancy, patients with comorbidities)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical deterioration or lack of clinical improvement with defervescence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant bleeding (epistaxis, hematemesis, melena, hematuria, or excessive menstrual bleeding)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered consciousness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty with follow-up</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family concern/anxiety</p><p></p><p>Published experience with systematic application of more restrictive criteria for admission of patients with suspected dengue is limited. This includes an uncontrolled study in Malaysia conducted over a two-month period [<a href="#rid63">63</a>] and case series from Singapore describing the clinical experience with institutional admissions guidelines [<a href="#rid64">64</a>]. The major criteria for hospitalization in those sites included:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure &lt;90/60 mmHg</p><p class="bulletIndent1"><span class="glyph">●</span>Hematocrit &gt;50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;50,000/mm<sup>3</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of bleeding other than petechiae</p><p></p><p>Additional criteria for hospitalization in the Singapore study included pulse ≥100 beats/minute, severe abdominal pain, persistent vomiting, and older adult patients with comorbidities. Both groups reported successful management with no complications resulting from outpatient care; however, the studies involved only adults, and the number of cases of severe dengue/dengue hemorrhagic fever (DHF) was relatively small (28 in Malaysia and 148 in Singapore). In case series in Thailand and Singapore, the WHO criteria for dengue with warning signs of severe infection would have led to an excess of hospitalizations and/or treatment relative to local clinical practice [<a href="#rid64">64,65</a>].</p><p>Routine laboratory testing is not readily available in many resource-limited settings where dengue is endemic. One study including 1250 children aged 2 months to 10 years in southern Vietnam evaluated whether an assessment tool using only clinical signs could appropriately guide management of acute illness [<a href="#rid66">66</a>]. The assessment tool was derived from the WHO/United Nations Children's Emergency Fund (UNICEF) "Integrated Management of Childhood Illness" algorithm designed for use in Africa and was modified to include common signs and symptoms of DHF. The 20 children who presented with dengue shock syndrome were correctly identified as requiring urgent hospitalization, although classification of less severe DHF was imperfect, and reevaluation within one to two days was needed to detect children who developed shock.</p><p>Several studies have applied decision-tree analysis to develop algorithms for early management of patients with suspected dengue, although the study populations and conclusions have differed [<a href="#rid67">67-70</a>]. Until these findings can be externally validated in a prospective fashion, the use of any of these algorithms in clinical practice cannot be recommended.</p><p class="headingAnchor" id="H14"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>Thus far, data do not support a role for corticosteroids [<a href="#rid71">71-73</a>], intravenous immunoglobulins, <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, or activated factor VII [<a href="#rid74">74-76</a>].</p><p>Several approaches are under investigation for specific treatment of dengue, including direct viral inhibitors and modifiers of virus-host interactions [<a href="#rid77">77,78</a>]. Direct-acting agents have included small molecule inhibitors of essential viral enzymes (NS2B-3 protease, NS3 helicase, NS5 methyltransferase, the NS5 polymerase) or small molecule or antibody inhibitors of viral entry/fusion. A dengue mouse model has been validated and demonstrated to be a suitable test system for direct viral inhibitors [<a href="#rid79">79</a>]. Several agents have demonstrated reduction of viremia and levels of proinflammatory cytokines in this model [<a href="#rid80">80</a>].</p><p>Randomized trials of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, balapiravir (a polymerase inhibitor), and celgosivir (an alpha-glucosidase inhibitor) among adults with dengue have not noted a significant benefit on viremia, NS1 antigenemia, or fever [<a href="#rid81">81-83</a>].</p><p class="headingAnchor" id="H555668104"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118425.html" rel="external">"Society guideline links: Dengue virus"</a>.)</p><p class="headingAnchor" id="H99088671"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83159.html" rel="external">"Patient education: Dengue fever (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H846381"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Dengue is a febrile illness that is caused by one of four dengue virus (DENV) types (DEN-1, DEN-2, DEN-3, and DEN-4). The likelihood for development of severe dengue is highest among individuals who develop a second dengue infection caused by a different virus type from the first infection. Thus, severe disease occurs primarily among individuals in areas where multiple DENV types circulate simultaneously. (See <a class="local">'Introduction'</a> above and <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approaches for prevention of dengue infection in endemic areas include mosquito control and vaccine development. Mosquito control is effective but is difficult to sustain. A single vaccine, CYD-TDV, has been licensed in several countries in Latin America, Southeast Asia, Europe, and the United States. CYD-TDV should be administered only to individuals with history of previous DENV infection or laboratory evidence of previous DENV infection. (See <a class="local">'In endemic areas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most travelers from nonendemic countries are at low risk for severe dengue in the absence of prior DENV exposure; potential exceptions include frequent international travelers, expatriates, frequently deploying military personnel, and immigrants from endemic areas returning to their countries of origin. (See <a class="local">'Among travelers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with suspected dengue should be assessed carefully and directed to the appropriate care setting. Early recognition of severe disease and patients at increased risk for severe disease are essential, with prompt initiation of more aggressive therapy when necessary. (See <a class="local">'Phases of infection and clinical assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outpatient management is appropriate for patients with presumptive diagnosis of dengue in the absence of warning signs or coexisting condition (pregnancy, infancy, old age, diabetes, renal failure, underlying hemolytic disease, obesity, or poor social situation). Patients should be instructed to take plenty of fluids and watch for signs of dehydration. Inpatient management is warranted for patients with dengue and warning signs of severe infection, severe dengue infection, or dengue infection with coexisting conditions. (See <a class="local">'Outpatient management'</a> above and <a class="local">'Inpatient management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients warranting inpatient management should be assessed for signs of shock  (<a class="graphic graphic_table graphicRef109848" href="/z/d/graphic/109848.html" rel="external">table 1</a>). In the absence of shock, patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109849" href="/z/d/graphic/109849.html" rel="external">algorithm 1</a>). In the setting of shock (normal systolic pressure but rising diastolic pressure with narrowing pulse pressure), patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109851" href="/z/d/graphic/109851.html" rel="external">algorithm 2</a>). In the setting of profound or prolonged shock, patients may be managed as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef109850" href="/z/d/graphic/109850.html" rel="external">algorithm 3</a>). (See <a class="local">'Management of plasma leakage'</a> above and <a class="local">'Treatment of shock'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever and myalgias should be managed with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>; <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or nonsteroidal anti-inflammatory agents should be avoided. Gastrointestinal bleeding, epistaxis, or heavy menstrual bleeding may be severe enough to warrant blood transfusion. (See <a class="local">'Management of fever'</a> above and <a class="local">'Management of bleeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504.</a></li><li><a class="nounderline abstract_t">Mizumoto K, Ejima K, Yamamoto T, Nishiura H. On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis 2014; 51:153.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Dengue Case Management. http://www.cdc.gov/dengue/resources/DENGUE-clinician-guide_508.pdf (Accessed on September 08, 2015).</li><li class="breakAll">World Health Organization. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control, 2nd ed. WHO, Geneva 1997. http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/ (Accessed on September 13, 2016).</li><li class="breakAll">World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control, New edition. WHO, Geneva 2009. http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf (Accessed on September 13, 2016).</li><li class="breakAll">World Health Organization. Handbook for clinical management of dengue. WHO, Geneva 2012. https://apps.who.int/iris/bitstream/handle/10665/76887/9789241504713_eng.pdf?sequence=1&amp;isAllowed=y (Accessed on September 13, 2016).</li><li><a class="nounderline abstract_t">Vanlerberghe V, Villegas E, Oviedo M, et al. Evaluation of the effectiveness of insecticide treated materials for household level dengue vector control. PLoS Negl Trop Dis 2011; 5:e994.</a></li><li><a class="nounderline abstract_t">Loroño-Pino MA, García-Rejón JE, Machain-Williams C, et al. Towards a Casa Segura: a consumer product study of the effect of insecticide-treated curtains on Aedes aegypti and dengue virus infections in the home. Am J Trop Med Hyg 2013; 89:385.</a></li><li><a class="nounderline abstract_t">Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture. Am J Trop Med Hyg 1989; 40:571.</a></li><li><a class="nounderline abstract_t">Halstead SB. Selective primary health care: strategies for control of disease in the developing world. XI. Dengue. Rev Infect Dis 1984; 6:251.</a></li><li><a class="nounderline abstract_t">Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990.</a></li><li><a class="nounderline abstract_t">Monath TP. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med 2007; 357:2222.</a></li><li><a class="nounderline abstract_t">Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007; 77:910.</a></li><li><a class="nounderline abstract_t">Precioso AR, Palacios R, Thomé B, et al. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. Vaccine 2015; 33:7121.</a></li><li><a class="nounderline abstract_t">Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine 2015; 33 Suppl 4:D24.</a></li><li><a class="nounderline abstract_t">Prompetchara E, Ketloy C, Thomas SJ, Ruxrungtham K. Dengue vaccine: Global development update. Asian Pac J Allergy Immunol 2020; 38:178.</a></li><li class="breakAll">World Health Organization. Questions and Answers on Dengue Vaccines. http://www.who.int/immunization/research/development/dengue_q_and_a/en/ (Accessed on February 04, 2016).</li><li class="breakAll">World Health Organization. Weekly epidemiological record. Dengue vaccine: WHO position paper – September 2018. http://apps.who.int/iris/bitstream/handle/10665/274315/WER9336.pdf (Accessed on September 11, 2018).</li><li class="breakAll">European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018 (Accessed on January 28, 2022).</li><li class="breakAll">US Food and Drug Administration. First FDA-approved vaccine for the prevention of dengue disease in endemic regions. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions (Accessed on May 02, 2019).</li><li><a class="nounderline abstract_t">Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632.</a></li><li><a class="nounderline abstract_t">Thomas SJ, Yoon IK. A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother 2019; 15:2295.</a></li><li><a class="nounderline abstract_t">Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358.</a></li><li><a class="nounderline abstract_t">Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113.</a></li><li><a class="nounderline abstract_t">Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med 2018; 379:327.</a></li><li><a class="nounderline abstract_t">Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med 2015; 373:1195.</a></li><li><a class="nounderline abstract_t">Olivera-Botello G, Coudeville L, Fanouillere K, et al. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America. J Infect Dis 2016; 214:994.</a></li><li class="breakAll">Sanofi. Sanofi updates information on dengue vaccine, December 4, 2017. https://www.sanofi.com/en/media-room/articles/2017/information-update-on-dengvaxia (Accessed on February 21, 2020).</li><li class="breakAll">World Health Organization. Updated Questions and Answers related to information presented in the Sanofi Pasteur press release on 30 November 2017 with regards to the dengue vaccine Dengvaxia, 30th November 2017. http://www.who.int/immunization/diseases/dengue/q_and_a_dengue_vaccine_dengvaxia/en/ (Accessed on December 29, 2017).</li><li><a class="nounderline abstract_t">Moodie Z, Juraska M, Huang Y, et al. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. J Infect Dis 2018; 217:742.</a></li><li><a class="nounderline abstract_t">Nascimento EJM, George JK, Velasco M, et al. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods 2018; 257:48.</a></li><li class="breakAll">Dengvaxia. Tetravalent, Live-Attenuated Viral Vaccine against Dengue Serotypes 1, 2, 3 and 4: Briefing Document for the Vaccines and Related Biological Products Advisory Committee. https://www.fda.gov/media/120943/download (Accessed on July 02, 2019).</li><li><a class="nounderline abstract_t">Sáez-Llorens X, Tricou V, Yu D, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 2018; 18:162.</a></li><li><a class="nounderline abstract_t">Tricou V, Sáez-Llorens X, Yu D, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet 2020; 395:1434.</a></li><li><a class="nounderline abstract_t">Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med 2019; 381:2009.</a></li><li><a class="nounderline abstract_t">Biswal S, Borja-Tabora C, Martinez Vargas L, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 2020; 395:1423.</a></li><li><a class="nounderline abstract_t">Andersson N, Nava-Aguilera E, Arosteguí J, et al. Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. BMJ 2015; 351:h3267.</a></li><li><a class="nounderline abstract_t">Kay B, Vu SN. New strategy against Aedes aegypti in Vietnam. Lancet 2005; 365:613.</a></li><li><a class="nounderline abstract_t">Hales S, van Panhuis W. A new strategy for dengue control. Lancet 2005; 365:551.</a></li><li><a class="nounderline abstract_t">Iturbe-Ormaetxe I, Walker T, O' Neill SL. Wolbachia and the biological control of mosquito-borne disease. EMBO Rep 2011; 12:508.</a></li><li><a class="nounderline abstract_t">Lambrechts L, Ferguson NM, Harris E, et al. Assessing the epidemiological effect of wolbachia for dengue control. Lancet Infect Dis 2015; 15:862.</a></li><li><a class="nounderline abstract_t">Ryan PA, Turley AP, Wilson G, et al. Establishment of wMel Wolbachia in Aedes aegypti mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland, Australia. Gates Open Res 2019; 3:1547.</a></li><li><a class="nounderline abstract_t">Flores HA, Taneja de Bruyne J, O'Donnell TB, et al. Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in Aedes aegypti. PLoS Pathog 2020; 16:e1008433.</a></li><li><a class="nounderline abstract_t">Utarini A, Indriani C, Ahmad RA, et al. Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue. N Engl J Med 2021; 384:2177.</a></li><li class="breakAll">WHO Regional Office for Southeast Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded version. SEARO Technical Publication Series, New Delhi 2011.</li><li><a class="nounderline abstract_t">Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.</a></li><li><a class="nounderline abstract_t">Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204.</a></li><li><a class="nounderline abstract_t">Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis 1999; 29:787.</a></li><li><a class="nounderline abstract_t">Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877.</a></li><li><a class="nounderline abstract_t">Ferreira BDC, Correia D. Ultrasound Assessment of Hepatobiliary and Splenic Changes in Patients With Dengue and Warning Signs During the Acute and Recovery Phases. J Ultrasound Med 2019; 38:2015.</a></li><li><a class="nounderline abstract_t">Colbert JA, Gordon A, Roxelin R, et al. Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J 2007; 26:850.</a></li><li><a class="nounderline abstract_t">Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis 2013; 57:1577.</a></li><li><a class="nounderline abstract_t">Mitrakul C, Poshyachinda M, Futrakul P, et al. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:975.</a></li><li><a class="nounderline abstract_t">Thomas L, Kaidomar S, Kerob-Bauchet B, et al. Prospective observational study of low thresholds for platelet transfusion in adult dengue patients. Transfusion 2009; 49:1400.</a></li><li><a class="nounderline abstract_t">Khan Assir MZ, Kamran U, Ahmad HI, et al. Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. Transfus Med Hemother 2013; 40:362.</a></li><li><a class="nounderline abstract_t">Lye DC, Lee VJ, Sun Y, Leo YS. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis 2009; 48:1262.</a></li><li><a class="nounderline abstract_t">Lye DC, Archuleta S, Syed-Omar SF, et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet 2017; 389:1611.</a></li><li><a class="nounderline abstract_t">Kansay S, Singh H. Effect of introduction of single-donor apheresis platelets in dengue management: A comparative analysis of two consecutive dengue epidemics. J Lab Physicians 2018; 10:173.</a></li><li><a class="nounderline abstract_t">Rajapakse S, de Silva NL, Weeratunga P, et al. Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review. Trans R Soc Trop Med Hyg 2017; 111:433.</a></li><li class="breakAll">Kalayanarooj S. The Southeast Asia Regional Office (WHO) Guidelines for Clinical Management of Dengue and Dengue Hemorrhagic Fever. In: Dengue and Dengue Hemorrhagic Fever, 2nd ed, Gubler DG, Ooi EE, Vasudeva S, Farrar J (Eds), CAB International, Oxfordshire, UK 2014.</li><li class="breakAll">Clinical Practice Guidelines of Dengue/Dengue Hemorrhagic Fever Management for Asian Economic Community, Kalayanarooj S, Vangveeravong M, Vatcharasaevee V (Eds), Bangkok Medical Publisher, Bangkok 2014.</li><li><a class="nounderline abstract_t">Chin CK, Kang BH, Liew BK, et al. Protocol for out-patient management of dengue illness in young adults. J Trop Med Hyg 1993; 96:259.</a></li><li><a class="nounderline abstract_t">Leo YS, Gan VC, Ng EL, et al. Utility of warning signs in guiding admission and predicting severe disease in adult dengue. BMC Infect Dis 2013; 13:498.</a></li><li><a class="nounderline abstract_t">Kalayanarooj S. Dengue classification: current WHO vs. the newly suggested classification for better clinical application? J Med Assoc Thai 2011; 94 Suppl 3:S74.</a></li><li><a class="nounderline abstract_t">Cao XT, Ngo TN, Kneen R, et al. Evaluation of an algorithm for integrated management of childhood illness in an area of Vietnam with dengue transmission. Trop Med Int Health 2004; 9:573.</a></li><li><a class="nounderline abstract_t">Tanner L, Schreiber M, Low JG, et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis 2008; 2:e196.</a></li><li><a class="nounderline abstract_t">Lee VJ, Lye DC, Sun Y, Leo YS. Decision tree algorithm in deciding hospitalization for adult patients with dengue haemorrhagic fever in Singapore. Trop Med Int Health 2009; 14:1154.</a></li><li><a class="nounderline abstract_t">Potts JA, Gibbons RV, Rothman AL, et al. Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. PLoS Negl Trop Dis 2010; 4:e769.</a></li><li><a class="nounderline abstract_t">Nguyen MT, Ho TN, Nguyen VV, et al. An Evidence-Based Algorithm for Early Prognosis of Severe Dengue in the Outpatient Setting. Clin Infect Dis 2017; 64:656.</a></li><li><a class="nounderline abstract_t">Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006; :CD003488.</a></li><li><a class="nounderline abstract_t">Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 55:1216.</a></li><li><a class="nounderline abstract_t">Zhang F, Kramer CV. Corticosteroids for dengue infection. Cochrane Database Syst Rev 2014; :CD003488.</a></li><li><a class="nounderline abstract_t">Dimaano EM, Saito M, Honda S, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007; 77:1135.</a></li><li><a class="nounderline abstract_t">Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis 2005; 16:549.</a></li><li><a class="nounderline abstract_t">Salgado D, Zabaleta TE, Hatch S, et al. Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. Pediatr Infect Dis J 2012; 31:771.</a></li><li><a class="nounderline abstract_t">Noble CG, Shi PY. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 2012; 96:115.</a></li><li><a class="nounderline abstract_t">Krishnan MN, Garcia-Blanco MA. Targeting host factors to treat West Nile and dengue viral infections. Viruses 2014; 6:683.</a></li><li><a class="nounderline abstract_t">Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 1999; 73:783.</a></li><li><a class="nounderline abstract_t">Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007; 195:665.</a></li><li><a class="nounderline abstract_t">Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013; 207:1442.</a></li><li><a class="nounderline abstract_t">Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 2014; 14:706.</a></li><li><a class="nounderline abstract_t">Whitehorn J, Nguyen CV, Khanh LP, et al. Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis 2016; 62:468.</a></li></ol></div><div id="topicVersionRevision">Topic 3030 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563266" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The global distribution and burden of dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253207" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253207" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253207" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253207" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468313" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation of the effectiveness of insecticide treated materials for household level dengue vector control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23732254" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Towards a Casa Segura: a consumer product study of the effect of insecticide-treated curtains on Aedes aegypti and dengue virus infections in the home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2472746" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6374837" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Selective primary health care: strategies for control of disease in the developing world. XI. Dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999601" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046026" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dengue and yellow fever--challenges for the development and use of vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984352" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26458796" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26122583" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Trials and tribulations on the path to developing a dengue vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660171" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dengue vaccine: Global development update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660171" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dengue vaccine: Global development update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660171" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dengue vaccine: Global development update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660171" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dengue vaccine: Global development update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660171" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dengue vaccine: Global development update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34978547" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808029" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31589551" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A review of Dengvaxia®: development to deployment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018116" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25365753" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of a tetravalent dengue vaccine in children in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897841" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26214039" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418050" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418050" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418050" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29194547" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567514" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567514" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122463" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32197107" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693803" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32197105" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156323" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708107" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : New strategy against Aedes aegypti in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708083" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A new strategy for dengue control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546911" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Wolbachia and the biological control of mosquito-borne disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26051887" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Assessing the epidemiological effect of wolbachia for dengue control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31667465" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Establishment of wMel Wolbachia in Aedes aegypti mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282862" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in Aedes aegypti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34107180" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34107180" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237695" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Early clinical and laboratory indicators of acute dengue illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170909" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589889" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135832" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparison of three fluid solutions for resuscitation in dengue shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30549307" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ultrasound Assessment of Hepatobiliary and Splenic Changes in Patients With Dengue and Warning Signs During the Acute and Recovery Phases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721386" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046311" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/907057" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hemostatic and platelet kinetic studies in dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320862" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prospective observational study of low thresholds for platelet transfusion in adult dengue patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24273491" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19292665" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283286" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29692583" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of introduction of single-donor apheresis platelets in dengue management: A comparative analysis of two consecutive dengue epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385613" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385613" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385613" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345549" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Protocol for out-patient management of dengue illness in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24152678" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Utility of warning signs in guiding admission and predicting severe disease in adult dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22043757" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dengue classification: current WHO vs. the newly suggested classification for better clinical application?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117301" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evaluation of an algorithm for integrated management of childhood illness in an area of Vietnam with dengue transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18335069" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624479" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Decision tree algorithm in deciding hospitalization for adult patients with dengue haemorrhagic fever in Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20689812" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034883" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An Evidence-Based Algorithm for Early Prognosis of Severe Dengue in the Outpatient Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856011" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Corticosteroids for treating dengue shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22865871" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24984082" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Corticosteroids for dengue infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165536" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269927" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22481426" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Use of pentoxifylline in treatment of children with dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995600" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Structural biology of dengue virus enzymes: towards rational design of therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24517970" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Targeting host factors to treat West Nile and dengue viral infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847388" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : New mouse model for dengue virus vaccine testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262707" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22807519" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24877997" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565005" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
